Lantern Pharma Inc. Insurance Commissions and Fees
Lantern Pharma Inc. (LTRN) reported Insurance Commissions and Fees of $1.26 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Notes
us-gaap:InsuranceCommissionsAndFees · last filed 2020-10-29
- Lantern Pharma Inc. insurance commissions and fees for the quarter ending 2020-09-30 was $1.25M.
| Period end | Insurance Commissions and Fees 3 month | Insurance Commissions and Fees 6 month | Insurance Commissions and Fees 9 month |
|---|---|---|---|
| 2020-09-30 | $1.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $1.26M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $7.00K 10-Q · filed 2020-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |